What is HC Wainwright’s Estimate for MLYS FY2030 Earnings?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – HC Wainwright issued their FY2030 earnings estimates for Mineralys Therapeutics in a note issued to investors on Monday, January 26th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of $4.41 per share for the year. HC Wainwright has a “Buy” rating and a $56.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.23) per share.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company upped their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Stifel Nicolaus raised their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Mineralys Therapeutics Price Performance

Shares of NASDAQ:MLYS opened at $32.34 on Tuesday. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of -10.96 and a beta of 0.49. The business’s fifty day moving average price is $36.55 and its two-hundred day moving average price is $32.19. Mineralys Therapeutics has a fifty-two week low of $8.24 and a fifty-two week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14.

Insiders Place Their Bets

In related news, insider David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $35.02, for a total value of $6,748,879.30. Following the completion of the sale, the insider directly owned 61,804 shares in the company, valued at $2,164,376.08. This trade represents a 75.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alexander M. Gold sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $43.98, for a total value of $659,700.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,686,955 shares of company stock valued at $71,118,551 over the last 90 days. Corporate insiders own 33.24% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Mineralys Therapeutics by 51.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Mineralys Therapeutics by 198.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after purchasing an additional 676 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Mineralys Therapeutics by 42.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after purchasing an additional 1,197 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Mineralys Therapeutics in the 2nd quarter valued at approximately $91,000. Finally, Russell Investments Group Ltd. increased its stake in Mineralys Therapeutics by 14,091.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock worth $124,000 after purchasing an additional 3,241 shares in the last quarter. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.